Related to FDA Clears Qiagen’s Rotor-Gene MDx RT-PCR IVD Platform and Influenza Assay

• FDA Asks Spectrum Pharmaceuticals for Past Clinical Study Data to Help Expand Approval of NHL Drug
  
• Protalix’ Phase III Candidate for Gaucher’s May Fill the Treatment Gap due to Genzyme’s Plant Closure
  
• Shire’s Gaucher Disease Drug Candidate Being Considered by FDA
  
• Spinreact to Include AbD Serotec Antibodies in Clinical Diagnostic Kits
  
• FDA Gives Osmetech’s Cystic Fibrosis Genotyping Test a Thumbs Up
  
• DxS and Epigenomics Cross-License Technologies for DNA Methylation In Vitro Diagnostics
  
• FDA Says Erbitux No Good for Those with Certain K-ras Mutations
  
• Medicago and Genopole to Set Up Plant in France for Influenza Vaccine Production
  
• FDA Clears Novartis Medication as Initial Therapy for Blood Pressure
  
• Axial Biotech Selects University of Utah Database to Develop Personalized Tests for Spine Disorders
  
• Cryopraxis to Assess Cryo-Cell's Menstrual Stem Cell Technology for Diagnosing Endometriosis
  
• QuantRx Creates Joint Venture with NuRx Focused on Point-of-Care Products
  
• FDA Gives Roche’s Avastin the Go-Ahead for Metastatic Renal Carcinoma
  
• MP Biomedicals to Develop Alzheimer’s Blood Test Based on UCLA Technology
  
• Novartis Starts Shipment of Seasonal Flu Vaccine to the U.S.
  
• Rosetta Genomics Taps Warnex as Canadian Distributor for Cancer Diagnostics
  
• Biota and Daiichi Sankyo’s Flu Therapy Shows Positive Phase III Results
  
• FDA Clears Sandoz’ Generic Competitor to Astellas Transplant Drug
  
• Arup Taps Epigenomics’ mSEPT9 Biomarker to Develop Colorectal Cancer Test
  
• FDA Sanctions Novartis’ MS Drug